Mantle Cell Lymphoma Articles

Flinn Sheds Light on Advances in MCL and Other Lymphomas
Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.
Ibrutinib Continues to Demonstrate Effectiveness in MCL
Brad S. Kahl, MD, discusses the latest data for ibrutinib and highlights emerging treatments in mantle cell lymphoma. 
Combinations Explored in MCL After Second BTK Inhibitor Approval
Brian T. Hill, MD, PhD, discusses acalabrutinib and ibrutinib’s efficacy in patients with mantle cell lymphoma and highlights emerging novel strategies in the treatment landscape.
MCL Expert Highlights Recent Advancements in Field
Peter Martin, MD, reflects on the MCL data presented at the 2017 ASH Annual Meeting, and shares his insight on the future of clinical trials in the disease.
Frontline Lenalidomide/Rituximab Combo Warrants Further Investigation in MCL
Jia Ruan, MD, PhD, discusses the pivotal analysis of the combination of lenalidomide plus rituximab, as well as the next steps for this regimen in the field of mantle cell lymphoma.
Long-Term Ibrutinib Follow-up Demonstrates Continued Efficacy in MCL
More than one-quarter of patients with relapsed/refractory mantle cell lymphoma remained progression free and nearly half were alive at 3 years when treated with the BTK inhibitor ibrutinib (Imbruvica). 
NICE Recommends Ibrutinib for Relapsed/Refractory MCL
The United Kingdom's National Institute for Health Care and Excellence has published new guidelines recommending ibrutinib as treatment for patients with relapsed/refractory mantle cell lymphoma.
Expert Emphasizes Importance of Acalabrutinib Approval in MCL
Michael Wang, MD, discusses the impact of acalabrutinib on patients with mantle cell lymphoma, ongoing progress in the field, and The University of Texas MD Anderson Cancer Center
Goy Reflects on MCL Data Presented at ASH 2017
Andre Goy, MD, sheds light on some studies as well as future treatment options for patients with mantle cell lymphoma (MCL).
Acalabrutinib Highly Effective for Refractory MCL
Acalabrutinib demonstrated an objective response rate of 81% with a complete response rate of 40% for patients with refractory mantle cell lymphoma.
Publication Bottom Border
Border Publication